Axios: Higher US drug prices don’t translate to better health

Amy Baxter | | Health Exec | Policy & Regulations
Researchers found millions of heart failure patients who qualify for standard, guideline directed medical therapies, but did not receive it due to poor health literacy, limited access to care and medication costs.

The United States pays far more for prescription drugs than other countries, but health outcomes aren’t much better––and sometimes, they’re worse––according to Axios.

The pharmaceutical industry frequently justifies its higher prices by arguing it provides resources for research and development. However, being unable to pay for these drugs could void that argument or at least bring up questions about why consumers have to pay so much.

At the same time, the prices do not reflect quality, or better care. The United States was ranked last in healthcare outcomes in a 2017 Commonwealth Fund report that weighted 10 other wealthy countries.

While health outcomes have yet to improve, the Trump administration continues to propose new initiatives to lower prescription drug prices in Medicare.

See the full story below:

U.S. drug prices don't translate to better health

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.